ContraFect CorpOver The Counter Market:CFRXQ
- LAST PRICE0.0000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots---/ ---
- Ask / Lots---/ ---
- Open / Previous Close0.1400 / 0.0000
- Day Range
- 52 Week Range
- Volume2,312
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CFRXQ |
|---|---|---|
| 11:23 ET | 2200 | 1E-06 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ContraFect Corp | 10.0 | 0.0x | --- |
OncoSec Medical Inc | 10.0 | 0.0x | --- |
PZ Wind Down Inc | 10.0 | 0.0x | --- |
Cantabio Pharmaceuticals Inc | 22.8K | 0.0x | --- |
Regnum Corp | 20.0 | 0.0x | --- |
Eloxx Pharmaceuticals Inc | 310.0 | 0.0x | --- |
Company Information
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
Contact Information
- Headquarters
- 28 Wells Avenue, 3rd FloorYONKERS, NY, United States 10701
- Phone
- 914-207-2300
- Fax
- 302-636-5454
Executives
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $10.00 |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
ContraFect Corp does not pay a dividend. | |
Beta | 6.59 |
EPS | $-19.25 |
Book Value | $-19.92 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
